{
    "clinical_study": {
        "@rank": "28568", 
        "arm_group": [
            {
                "arm_group_label": "PF-045 / PF-045", 
                "arm_group_type": "Experimental", 
                "description": "First treatment with PF-045 with potential to re-treat with PF-045, if necessary."
            }, 
            {
                "arm_group_label": "PF-055 / PF-055", 
                "arm_group_type": "Experimental", 
                "description": "First treatment with PF-055 with potential to re-treat with PF-055, if necessary."
            }, 
            {
                "arm_group_label": "Vehicle / PF-045", 
                "arm_group_type": "Placebo Comparator", 
                "description": "First treatment with Vehicle with potential to re-treat with PF-045, if necessary."
            }, 
            {
                "arm_group_label": "Vehicle / PF-055", 
                "arm_group_type": "Placebo Comparator", 
                "description": "First treatment with Vehicle with potential to re-treat with PF-055, if necessary."
            }
        ], 
        "brief_summary": {
            "textblock": "To determine and compare the safety and efficacy of PF-045 and PF-055 with that of vehicle\n      in subjects with scabies. It is anticipated that a majority of subjects will require and\n      receive a single treatment; however, those subjects not showing improvement at the follow-up\n      visit 2 weeks after initial treatment will be treated a second time.  Those subjects\n      originally assigned to vehicle for the first treatment will receive a \"re-treatment\" with\n      one of the active doses."
        }, 
        "brief_title": "A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of PF-045 and PF-055 for the Treatment of Scabies", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Scabies", 
        "condition_browse": {
            "mesh_term": "Scabies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of active scabies infection.\n\n          -  Subject is in good general health with normal appearing skin in noninfested areas.\n\n          -  Females must be post-menopausal, surgically sterile or use an effective method of\n             birth control with a negative pregnancy test (10 years of age and older) at study\n             start.\n\n        Exclusion Criteria:\n\n          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.\n\n          -  Subject has used any ectoparasiticide within the three weeks prior to study start.\n\n          -  Subject has signs of systemic infection or is receiving systemic therapy for an\n             infectious disease.\n\n          -  Subject has severe cutaneous bacterial or fungal infections requiring therapy or\n             heavily crusted lesions consistent with Norwegian scabies.\n\n          -  Subject is currently enrolled in an investigational drug or device study or has used\n             an investigational drug or device within 30 days prior to study start.\n\n          -  Subject whose close personal contacts will not comply with standard of care for\n             fomite management."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094716", 
            "org_study_id": "185-7851-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PF-045 / PF-045", 
                    "Vehicle / PF-045"
                ], 
                "description": "Topical application, single whole-body treatment", 
                "intervention_name": "PF-045", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "PF-055 / PF-055", 
                    "Vehicle / PF-055"
                ], 
                "description": "Topical application, single whole-body treatment", 
                "intervention_name": "PF-055", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Vehicle / PF-045", 
                    "Vehicle / PF-055"
                ], 
                "description": "Topical application, single whole-body treatment", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Sarcoptes", 
            "Scabiei", 
            "Scabies", 
            "ectoparasite", 
            "parasite", 
            "infestation", 
            "Renaissance"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fremont", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Clinical Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Clinical Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hialeah", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Clinical Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Clinical Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Clinical Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Randomized, Double-Blind, Parallel Group Comparison Study of the Safety and Efficacy of PF-055 Versus PF-045 Versus Vehicle in Subjects With Sarcoptes Scabiei", 
        "overall_contact": {
            "email": "okhatsenko@therapeuticsinc.com", 
            "last_name": "Oleg Khatsenko, PhD"
        }, 
        "overall_official": {
            "affiliation": "acarrier@renaissancepharmainc.com", 
            "last_name": "Alain Carrier, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\"Treatment success\" is defined as achieving an Investigator Global Assessment (IGA) score of 0 or 1 at Day 28 (i.e., following a single full-body treatment).  IGA measures scabies disease status on a 5-point scale (0=clear to 4=severe).", 
            "measure": "Proportion of subjects designated as \"treatment success\"", 
            "safety_issue": "No", 
            "time_frame": "Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094716"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The change in the signs/symptoms related to the disease in each treatment group at Days 14 and 28, as well as at Day 42 for those subjects provided with re-treatment at Day 14 who show improvement in their IGA score at Day 28.", 
                "measure": "Change in disease-related signs and symptoms", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 14, 28, and 42"
            }, 
            {
                "description": "The proportion of subjects re-treated at Day 14 designated as \"treatment success\" (IGA score of 0 or 1) at Day 42.", 
                "measure": "Proportion of re-treated subjects designated as \"treatment success\"", 
                "safety_issue": "No", 
                "time_frame": "Day 42"
            }, 
            {
                "description": "The proportion of subjects designated as \"treatment success\" (IGA score of 0 or 1) following one treatment versus two treatments. Subjects originally assigned to vehicle treatment and re-treated on Day 14 with an active dose will be included with the single treatment group for this analysis.", 
                "measure": "Proportion of subjects designated as \"treatment success\" following one treatment with an active dose", 
                "safety_issue": "No", 
                "time_frame": "Day 28 and Day 42"
            }
        ], 
        "source": "Renaissance Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Renaissance Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}